40.4 Other Dermatologic Condition Drugs and Topical Anti-infectives for Burns

Dermatologic Condition Drugs and Topical Anti-infectives for Burns

Skin conditions and burns require targeted topical therapies that address inflammation, infection, and pain at the tissue level. Nurses need to understand how these drugs work, their risks, and the correct way to apply them, since improper use can delay healing or cause serious adverse effects.

This section covers topical corticosteroids, calcineurin inhibitors, retinoids, burn-specific antibiotics, and topical anesthetics.

Key Drug Categories

Topical corticosteroids reduce inflammation, itching, and redness. They come in a range of potencies:

• Low potency: hydrocortisone (safe for face, skin folds)
• Medium potency: triamcinolone
• High/super-high potency: clobetasol (reserved for thick-skinned areas or severe flares)

Potency selection matters. Using a high-potency steroid on thin skin (face, groin) greatly increases the risk of local side effects like skin atrophy.

Topical calcineurin inhibitors (tacrolimus, pimecrolimus) treat atopic dermatitis and other inflammatory skin conditions by suppressing the local immune response. These are particularly useful as steroid-sparing alternatives for sensitive areas like the face and skin folds, where prolonged corticosteroid use is risky.

Topical retinoids (tretinoin, adapalene, tazarotene) treat acne and photodamaged skin by regulating skin cell turnover and differentiation. They unclog pores and reduce acne lesions over time, but results take weeks to appear. Patients often experience a temporary worsening of acne during the first few weeks of treatment.

Topical antibiotics for burns prevent and treat bacterial infection in burn wounds:

• Silver sulfadiazine is the most commonly used; provides broad-spectrum coverage. Contraindicated in sulfa allergy and should not be used in pregnant women near term or in newborns.
• Mafenide acetate penetrates eschar well, making it useful for deep burns, but it can cause metabolic acidosis (it inhibits carbonic anhydrase) and significant pain on application.
• Bacitracin is used for minor burns and superficial wounds.

Topical anesthetics (lidocaine, benzocaine) provide local pain relief for burn wounds by blocking sodium channels and preventing nerve impulse transmission.

Mechanisms, Effects, and Risks

A few risks to highlight for exams:

• Calcineurin inhibitors carry an FDA black box warning about a possible link to lymphoma and skin malignancy. They should be used as second-line therapy and not in immunocompromised patients.
• Topical retinoids are teratogenic. Women of childbearing age must use effective contraception.
• Mafenide acetate's ability to cause metabolic acidosis is a commonly tested adverse effect. Monitor acid-base balance in patients receiving it over large burn areas.

Nursing Considerations for Administration

Before applying any topical medication:

1. Assess the skin condition or burn wound, noting size, depth, signs of infection, and pain level.
2. Verify the correct drug, concentration, and potency for the prescribed site.
3. Perform hand hygiene and use gloves (sterile technique for burn wounds).

Application guidelines by drug class:

• Corticosteroids: Apply a thin layer to affected areas only. Do not occlude (cover with airtight dressing) unless specifically prescribed, as occlusion increases absorption and side effect risk.
• Calcineurin inhibitors: Apply to affected areas, avoiding eyes and mucous membranes. Do not use with occlusive dressings.
• Retinoids: Apply in the evening only (UV light degrades the drug and worsens photosensitivity). Use a pea-sized amount for the entire face. Wait until skin is completely dry after washing before applying, since moisture increases irritation.
• Burn antibiotics: Apply using sterile technique. Reapply as directed, typically after wound cleansing and debridement. Monitor for signs of systemic absorption with large surface area burns.
• Topical anesthetics: Apply to intact or superficial wound surfaces as needed. Avoid applying to large body surface areas to prevent systemic absorption and toxicity.

Ongoing monitoring:

• Watch for adverse effects: skin thinning with steroids, burning with calcineurin inhibitors, excessive peeling with retinoids, metabolic changes with mafenide.
• Assess wound healing progress and signs of infection (increased redness, warmth, purulent drainage, fever).
• Report unexpected reactions to the healthcare provider promptly.

Patient Education

• Purpose and expectations: Explain what the medication does and set realistic timelines. Retinoids, for example, may take 8 to 12 weeks to show full benefit, and initial worsening is normal.
• Application technique: Demonstrate how to apply the medication correctly. Emphasize "thin layer" for corticosteroids and "pea-sized amount" for retinoids. Patients tend to over-apply, which increases side effects without improving results.
• Sun protection: Patients using corticosteroids or retinoids should use broad-spectrum sunscreen (SPF 30 or higher), wear protective clothing, and avoid prolonged sun exposure. Retinoids make skin significantly more photosensitive.
• Side effects to report: Teach patients to contact their provider for signs of infection, worsening skin condition, unusual pain, or systemic symptoms (dizziness, irregular heartbeat with anesthetics; breathing changes with mafenide).
• Safety reminders:
  • Never share topical medications with others.
  • Store medications as directed (some retinoids are light-sensitive).
  • Women using retinoids must avoid pregnancy and discuss contraception with their provider.
• Adherence support: Encourage patients to keep a brief log of symptoms and treatment response. This helps the provider adjust therapy at follow-up visits and helps patients see their own progress over time.